CORE
CO
nnecting
RE
positories
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Research partnership
About
About
About us
Our mission
Team
Blog
FAQs
Contact us
Community governance
Governance
Advisory Board
Board of supporters
Research network
Innovations
Our research
Labs
Search results
>
Research work
EACVI survey on hypertrophic cardiomyopathy
Authors
Nina Ajmone Marsan
Matteo Cameli
+10 more
Nuno Cardim
Antonello D'Andrea
Marc R. Dweck
Kristina H. Haugaa
Gerald Maurer
Tomaz Podlesnikar
Bogdan A. Popescu
Jeanette Schulz-Menger
Ivan Stankovic
Janez Toplisek
Publication date
27 December 2021
Publisher
'Oxford University Press (OUP)'
Doi
Abstract
Publisher Copyright: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email:
[email protected]
: The European Association of Cardiovascular Imaging (EACVI) Scientific Initiatives Committee performed a global survey to evaluate current practice for the assessment and management of patients with hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: A total of 213 centres from 38 different countries (87% European) responded to the survey. One hundred twenty-one (57%) centres followed HCM patients in a general cardiology outpatient clinic and 85 (40%) centres in a specialized HCM/cardiomyopathy clinic. While echocardiography was the primary imaging modality, cardiovascular magnetic resonance (CMR) has become an important complementary tool. Cardiac anatomy, left ventricular (LV) systolic, and diastolic function were assessed according to current European guidelines and recommendations. To evaluate LV obstruction, 49% of the centres performed bedside provocation manoeuvres in every patient and 55% of the centres used exercise stress echocardiography. The majority of centres used the 5-year risk assessment of sudden cardiac death (SCD) calculated with the HCM Risk-SCD score. However, 34% of the centres also used extensive non-infarct late gadolinium enhancement on CMR and 27% the presence of LV apical aneurysm to help select patients for primary prevention implantable cardioverter-defibrillator therapy. Ninety-nine percent of the responding centres performed regular imaging follow-up of HCM patients. CONCLUSION: Most centres followed European guidelines and recommendations for the diagnosis and management of patients with HCM. The importance of bedside provocation manoeuvres and exercise stress echocardiography to diagnose LV outflow obstruction requires emphasis. Additional risk markers for SCD are used in many centres and might indicate the need for an update of current European recommendations.publishersversionpublishe
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Repositório da Universidade Nova de Lisboa
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:run.unl.pt:10362/137071
Last time updated on 20/05/2022
Archivio della Ricerca - Università degli Studi di Siena
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:usiena-air.unisi.it:11365/...
Last time updated on 20/06/2024
MDC Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:edoc.mdc-berlin.de:21208
Last time updated on 07/01/2022